Trial Profile
Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Pituitary ACTH hypersecretion; Pituitary tumours
- Focus Therapeutic Use
- 22 Feb 2011 Planned end date changed from 1 Dec 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 22 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 May 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.